Basic steps
Each step is hyperlinked to a brief demo video.
- Search the COVID-19 Register for studies
- Login to CRS Web & select COVID-19 Register (make sure you have ticked IN REGISTER as you do not want to search beyond this)
- Within the CRS Web search for study using the title or study ID
- Open annotation widget within the record to annotate
Annotation detail
Required | Not required | Notes | ||
---|---|---|---|---|
Population/Condition |
| |||
Intervention |
|
| If the study is comparing dosage please insert this data | |
Comparator |
| |||
Outcomes |
|
| For each outcome create a new group |
Terms not already in vocabulary
- our Vocabulary browser is available HERE
Not possible to complete the full annotation?
In some cases you will not be able to complete a full annotation. We ask that you:
- mark the annotation as Complete
- in the Annotation Action field in the CRS record select Vocabulary Request
- in the Annotation Notes field take note of the term requested
- request the missing term(s) in the Slack channel alerting Anna Last
- as soon as requested term(s) are available modify the annotation
- remove Vocabulary Request action
- remove the term requested from the Annotation Notes field
Priority studies to annotate
Important!
These may change over time depending on topics to be coved in rapid reviews.
For both priority 1 and 2 please search for
- studies with results (journal article or preprint article) then
- trial registry records
The reference type can be selected on our Study Register
Priority 1
Limit search to
- Study Reference Type: Journal Article/Preprint Article
- Intervention Assignment: Randomised
Any of the following interventions:
- Hand cleaning with ash
- Convalescent plasma, convalescent serum or convalescent hyperimmune immunoglobulin
- Any intervention in which a core component involves the use of the internet to facilitate video calls or video conferencing through computers, smartphones or tablets
- chloroquine, remdesivir, or corticosteroids
Priority 2
- Study Reference Type: Journal Article/Preprint Article
- Intervention Assignment: Non-randomised or Unclear or Quasi-randomised
Any of the following interventions:
- Hand cleaning with ash
- Convalescent plasma, convalescent serum or convalescent hyperimmune immunoglobulin
- Any intervention in which a core component involves the use of the internet to facilitate video calls or video conferencing through computers, smartphones or tablets
- chloroquine, remdesivir, or corticosteroids
Searching to identify priority trials
- Search on https://covid-19.cochrane.org/
- Restrict to Study Type: Interventional
- For the specific interventions:
- Text search for ash*
- Text search for convalescent
- etc.
Duplicate study records
You may come across some duplicate records where the same study has been imported from different sources (e.g. trials registers, pubmed).
If you find any:
- insert the study ID adn state 'duplicate' in the MISC 1 field
- annotate ONLY one record, preferably the published report (jnl article or preprint)
Topics/vocabulary
- Before you start annotating please check that the Cochrane Linked Data Vocabulary to determine whether or not terms are available
- If not available, place your request in the covid19-study-annotation channel in Slack and alert Anna last
Vocabulary notes
Age
A number of studies will state in their inclusion criteria Aged 18 years or older. Please annotate as:
Young Adult 19-24 years or Adult 19-44 years or Middle Aged 45-64 years or Aged 65-79 years or Aged 80 and over 80+ years |
Drug combinations
Use the individual drugs with AND
At Risk Of
In some studies the inclusion criteria population is 'At risk of ...' - in this case we do not annotate the condition in the Population but only as an Outcome.
Table of misc. terms and their categories
PICO | Topic | Domain Term | Category |
---|---|---|---|
I/C | Usual Care | Usual Care | Other |
I/C | Western Medicine | Usual Care | Pharmacological |
I/C | Symptomatic treatment | Usual Care | Other |
I/C | Plasma (and variants) | Cellular & Gene | |
I/C | Non-convalescent Plasma | Blood Plasma | Cellular & Gene |
I/C | Support or Supportive Care | Supportive Care | Other |
I/C | Liberal oxygen therapy | High Dose | Pharmacological |
I/C | Conservative oxygen therapy | Low Dose | Pharmacological |
O | Response rate | Therapeutic Response | Physiological or clinical |
O | Clinical response | Therapeutic Response | Physiological or clinical |
O | Response to treatment | Therapeutic Response | Physiological or clinical |
O | Clinical response to treatment | Therapeutic Response | Physiological or clinical |
O | Response to therapy | Therapeutic Response | Physiological or clinical |
O | Finding related to therapeutic response | Therapeutic Response | Physiological or clinical |
O | Complete response | Therapeutic Response | Physiological or clinical |
O | Blood Routine | Blood Test | Physiological or clinical |
O | Oxygen, ventilation etc (as requirements) | Physiological or clinical | |
O | Viral Load or Viral Cure | Viral Load | Physiological or clinical |
O | Oxygen supply, Oxygen Supplementation, Oxygen Independency etc. | Physiological or clinical | |
O | Hospital or ICU stay/duration of stay/ Admission to ... | Resource use | |
O | 2019-nCOVRNA in gargle | 2019-nCoV RT-PCR | Physiological or clinical |
O | Virus negative conversion | 2019-nCoV RT-PCR | Physiological or clinical |
O | Time for improvement of respiratory symptoms and signs (and similar) | Physiological or clinical | |
O | Time for temperature improvement (and similar) | Physiological or clinical | |
O | Sex-related differences in complications | Sex-related difference AND Complication | Physiological or clinical |
O | Breathing frequency | Rate of Respiration | Physiological or clinical |
O | Immunoglobulin G COVID-19 antibodies | Immunoglobulin G COVID-19 antibodies | Physiological or clinical |
O | Immunoglobulin M COVID-19 antibodies | Immunoglobulin M COVID-19 antibodies | Physiological or clinical |
O | Complete remission of clinical signs of disease | Clinical resolution | Physiological or clinical |
I/C | Quarantine | Quarantine | Behavioural |
O | Duration of ICU Stay | Length of ICU Stay | Resource Use |
O | Plasma Viscosity | Plasma viscosity measurement | Physiological or clinical |
O | Serum TNF-alpha level | Physiological or clinical |
Time to ...
Time to Clinical Improvement | https://data.cochrane.org/concepts/1ZAQeEkwo0cpmW |
Time to Clinical Recovery | https://data.cochrane.org/concepts/OW7PMP5pAaCBgR |
Time to defervescence | https://data.cochrane.org/concepts/6nyXkn9P8DIPG3 |
Time to cough | Cough |
Time to Dyspnea | Dyspnea |
Time till the virus nucleic acid test goes negative/ Transition time of novel coronavirus nucleic acid" |
Outcome annotation examples
Study | Outcome | Outcome detail | Annotation |
---|---|---|---|
NCT04278963 | respiratory progression | Defined as: SPO2≤ 93% on room air or PaO2/FiO2≤ 300mmHg and requirement for supplemental oxygen or more advanced ventilator support | Hypoxia AND (Oxygen therapy OR mechanical ventilation) - all in the same outcome group |